Global Primary Hyperoxaluria (PH) Treatment Market Insights Forecasts to 2030

• The Global Primary Hyperoxaluria Treatment Market Size was valued at USD 17.5 Million in 2022.
• The Market is growing at a CAGR of 8.7% from 2022 to 2032.
• The Worldwide Primary Hyperoxaluria Treatment Market size is expected to reach USD 40.6 Million by 2032.
• Asia Pacific is expected to grow the fastest during the forecast period.

Get more details on this report -

Request Free Sample PDF

The Global Primary Hyperoxaluria (PH) Treatment Market Size is expected to reach USD 40.6 Million by 2032, at a CAGR of 8.7% during the forecast period 2022 to 2032. The global primary hyperoxaluria treatment market is anticipated to rise due to rising healthcare costs in both developed and developing nations.

 

Market Overview

A rare inherited condition known as primary hyperoxaluria (PH) disrupts the capacity of the liver to process oxalate, causing kidney stones to form and irreversible kidney damage. Drugs and therapies for managing symptoms, preventing problems, and lowering oxalate production in the body make up the majority of the hyperoxaluria therapy market. Primary hyperoxaluria may present in a variety of ways and to varying degrees in different people. At the time of diagnosis, kidney failure, and chronic renal disease may already exist. Complications can be prevented by early diagnosis and treatment of primary hyperoxaluria, which is a treatable condition. The most severe and common primary hyperoxaluria subtype is I. 70 to 80 percent of people with primary hyperoxaluria are thought to be affected by it. Due to the disease's rarity, the primary hyperoxaluria therapy market is tiny; but, with Lumasiran's approval, there is an increasing interest in creating novel treatments for the ailment. Several businesses, such as Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, and Allena Pharmaceuticals, are currently developing drugs for primary hyperoxaluria. 

 

Report Coverage

This research report categorizes the global primary hyperoxaluria treatment market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global primary hyperoxaluria treatment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the global primary hyperoxaluria treatment market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.

 

 

Driving Factors

The primary hyperoxaluria treatment market is expected to grow significantly as a consequence of the rising prevalence of primary hyperoxaluria. Although the illness is rare, its incidence has been rising gradually in recent years. The market for the treatment of primary hyperoxaluria is expected to grow as a result of the rising prevalence of the condition, which would likely lead to an increase in demand for the diagnosis and treatment of the disease. Also, governments across the world are taking initiatives to raise awareness about primary hyperoxaluria and provide funding for the development of new therapies and drugs. This is expected to drive the growth of the market. Technological advancements in the field of diagnosis and treatment of primary hyperoxaluria have led to the development of innovative therapies and drugs, which are expected to drive the growth of the market. Moreover, the availability of reimbursement policies for the treatment of primary hyperoxaluria is expected to drive the growth of the market, as it makes treatment more accessible and affordable for patients.

 

Restraining Factors

Primary hyperoxaluria can be difficult to diagnose, as the symptoms are often vague and can be mistaken for other conditions. This can delay the diagnosis and treatment of the disorder, which is a major restraining factor for the market. Although a significant prevalence of primary hyperoxaluria, both the general population and medical experts are unaware of the condition. This is a significant market restraint since it prevents the adoption of efficient treatment solutions. The current treatment options for primary hyperoxaluria can cause side effects, which can be a major restraining factor for the market. The severity of the side effects can vary from patient to patient, and some patients may not tolerate the treatment. Moreover, Challenges in diagnosis may restrict the market growth during the forecast period.

 

Market Segmentation

• In 2022, the primary hyperoxaluria type I segment is dominating the market with the largest market share during the forecast period.

Based on the type, the global primary hyperoxaluria treatment market is classified into primary hyperoxaluria type I, primary hyperoxaluria type II, and primary hyperoxaluria type III. Among these, the hormone receptor segment is projecting significant growth due to Primary Hyperoxaluria Type I is the most common and severe form of the disorder. This type of primary hyperoxaluria is caused by a deficiency in the liver enzyme alanine-glyoxylate aminotransferase (AGT), which leads to the accumulation of oxalate in the body.

 

• In 2022, the injectable segment is influencing the largest market share over the forecast period.

The global primary hyperoxaluria treatment market is divided into oral and injectable based on the type of route of administration. During the projected period, the injectable segment will hold the greatest market share due to the only medication approved to treat primary hyperoxaluria is Lumasiran, which is injected via the subcutaneous route. Thus, the primary hyperoxaluria therapy market is thus anticipated by the subcutaneous injection route of administration. However, there are further treatments for primary hyperoxaluria that are presently in development. These treatments may employ various administration methods. For instance, several gene therapy strategies that would include the delivery of a therapeutic gene via a viral vector are currently being investigated. These treatments may be administered via intravenous infusion or another method.

 

• In 2022, the hospital pharmacies segment is driving market share growth during the forecast period.

On the basis of distribution channels, the global primary hyperoxaluria treatment market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, & others. Among these, the hospital pharmacies are expected to grow the market during the forecast period, owing to the specialized care and access to diagnostic resources and treatments that hospitals and specialist clinics offer, they are frequently the primary points of contact for patients with primary hyperoxaluria. Thus, the medication required for the treatment has been given by the hospital pharmacies. Additionally, patients with complex or severe instances of primary hyperoxaluria can receive thorough care at these clinics because of their knowledge and resources.

 

Regional Segment Analysis of the primary hyperoxaluria treatment Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is holding the market with the largest market share over the forecast period

 

Get more details on this report -

Request Free Sample PDF

 

North America is expected to account for the largest revenue share over the forecast period due to the value of the industry as a whole will rise if attractive reimbursement conditions are combined with access to cutting-edge treatment options. Modern healthcare facilities that provide the best possible care, high per capita healthcare spending by individuals, and awareness of common rare diseases are all contributing to the region's market growth. During the projected period, these factors are likely to increase the market share of the region.

 

Asia Pacific is expected to register significant revenue growth during the forecast period, owing to the market in the region being primarily driven by the growing elderly population. Also, the growing economies of India and China are reportedly the main drivers of the market for treatments of hyperoxaluria.

 

Competitive Analysis

The report offers the appropriate analysis of the key organizations/companies involved within the global primary hyperoxaluria treatment Market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Zhejiang Tianxin Pharmaceutical Co.
• Wuxi Further Pharmaceutical Co Ltd
• Tecoland Corporation
• Takeda Pharmaceuticals Company Limited
• Alnylam Pharmaceuticals, Inc.
• Genentech, Inc.
• Dicerna Pharmaceuticals, Inc.
• Pfizer Inc.
• Intellia Therapeutics, Inc.
• Allena Pharmaceuticals, Inc.

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

• In May 2022, according to Alnylam Pharmaceuticals, Inc., Health Canada approved the use of OXLUMO (lumasiran) injection for subcutaneous administration to adult and pediatric patients with primary hyperoxaluria type 1 (PH1) to reduce urinary oxalate levels.

 

• In March 2022, leading RNAi therapeutics company Alnylam Pharmaceuticals, Inc. announced that the USFDA has approved the company's additional New Drug Application (sNDA) for lumasiran, an investigational RNAi therapy that targets Hydroxyacid Oxidase 1 (HAO1), the gene that codes for Glycolate Oxidase (GO), to lower plasma oxalate in the treatment of individuals with primary hyperoxaluria type 1.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global Primary Hyperoxaluria Treatment Market based on the below-mentioned segments:

 

Global Primary Hyperoxaluria Treatment, By Type

• Primary Hyperoxaluria Type I
• Primary Hyperoxaluria Type II
• Primary Hyperoxaluria Type III

 

Global Primary Hyperoxaluria Treatment, By Route of Administration

• Oral
• Injectable

 

Global Primary Hyperoxaluria Treatment, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

 

Primary Hyperoxaluria Treatment, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa